July 17, 2014

TrialNetworks, Part of DrugDev, Adds Visual Intelligence to Award-Winning Clinical Trial Optimization System

TrialNetworks Charting™ app analyzes data from integrated clinical systems to provide study teams with dynamic charts displaying performance metrics and progress toward goals by region, country and site

NEWTON, Mass. & AUDUBON, Pa.-The award-winning Clinical Trial Optimization System from TrialNetworks, now part of DrugDev, continues to innovate with the introduction of its latest app. TrialNetworks Charting™ provides sponsors and CROs with visual intelligence into the study’s progress toward goals by region, country and site.

Charting automatically integrates data from external clinical systems (e.g. IXRS, CTMS, EDC) with operational metrics captured by the TrialNetworks platform (e.g. site activation status, final patient visit dates) to analyze performance over time and compared to plan. This level of insight enables study teams to quickly identify trends, make actionable recommendations and provide executive management with clear reports without spending time consolidating disparate and inconsistent spreadsheets.

Eric Silberstein, President of TrialNetworks, said, “The idea behind Charting started when our customers pointed out that we were already aggregating most of the information they use to track trial progress. Clinops team members suggested that a flexible charting capability would not only free them from manually assembling reports and charts in spreadsheets but would also let them make faster decisions. Charting enables these teams to generate visual reports using data from various systems in a matter of seconds. They can then use these reports as high-level status updates or segment them by region, country and site to review detailed performance trends.”

Charting will be included as an app within the TrialNetworks platform, which was awarded “Disruptive Technology of the Year” by Partnerships in Clinical Trials 2014. Charting data are easily exported into various formats and configured charts can be saved and shared among study team members.

Said Ibs Mahmood, DrugDev CEO, “We decided to acquire TrialNetworks because the platform makes running a clinical trial easier. I’m excited for customers to experience the new Charting app as it fits seamlessly into the platform and provides yet another level of efficient management for sponsor-site collaboration. As sponsors move to widespread deployment of TrialNetworks, senior clinical operations executives will be able to visualize all their trials through Charting yielding better insight and faster decision making.”

To request a demo of the TrialNetworks platform including Charting, visit

About DrugDev

DrugDev’s mission is to simplify life at the clinical trial site through technology. In this way DrugDev enables sponsors, CROs and investigators to do more trials together. Featuring the largest global network of active investigators, the industry’s leading grant payment and site contracting system in CFS Clinical (, and the award-winning TrialNetworks platform of clinical operations apps, DrugDev creates and drives standards which promote collaboration, improve quality, shorten timelines and reduce cost. In addition, DrugDev provides Hosted Data Solutions for clinical trials including hosting the Investigator Databank ( for Novartis, Janssen, Merck, Lilly and Pfizer. Learn more at

About TrialNetworks

TrialNetworks, part of DrugDev, provides sponsors and CROs with the award-winning Clinical Trial Optimization System to transform clinical operations quality and efficiency. Customers such as Merck & Co., Biogen Idec and Infinity Pharmaceuticals use this modern and intuitive technology to improve key aspects of a trial from feasibility through closeout. TrialNetworks apps, including Checklist™, Training™, Document Library™, Visit Guide™, Action Items™ and Directory™, are available in a unified and secure cloud-based interface. Customers ranging from biotechs to Top-10 pharma companies have implemented the TrialNetworks platform for use in Phase I-IV trials by more than 25,000 site staff in 60 countries. Request a demo